TMCnet

Insilico Initiates Phase III Clinical Trial for Rentosertib, Its AI-Empowered TNIK Inhibitor for Idiopathic Pulmonary Fibrosis

Insilico Medicine ("Insilico," HKEX: 3696), a clinical-stage biotechnology company powered by generative AI, today announced the initiation of the Phase III clinical trial for Rentosertib, its ...

Anthropic's new "J-lens" reveals a silent workspace inside Claude that mirrors a leading theory of consciousness

Anthropic’s new Claude research reveals a hidden internal “global workspace” that resembles human conscious processing, ...
TMCnet

Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory Board

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics. Strengthens strategic ...
Scientific Research Publishing

Radiation Therapy through Genetic Profiling: A Conceptual Framework for Radiogenomic Risk Stratification and Normal-Tissue Radioprotection ()

Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...

Akari Therapeutics Plc: Akari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific …

Globally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic ...
Lupus Science & Medicine

Upadacitinib enhances platelet procoagulant responses in a subset of healthy individuals and patients with SLE: a pilot study

Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...